Leon O Jr Moulder

CEO Leon O Jr Moulder bought 60,000 shares ($1.0M) at $16.88 on 2026-05-18, tripling holdings to 96,928 shares amid -62.1% decline from 52-week high.

Leon O Jr Moulder, CEO of Zenas BioPharma, purchased 60,000 shares for $1,012,800.00 at $16.88, expanding his holdings by 162.5% to 96,928 shares. The purchase occurs in a context of significant price deterioration: the stock trades at $16.91, down 62.1% from its 52-week high of $44.60 and down 22.5% over the past 30 days. Prior buys at ZBIO show mixed timing—4 of 5 were well-timed at the 90-day mark, with his two most recent purchases on 2026-04-29 and 2026-04-28 returning +4.1% and +1.8% at 90 days respectively. However, fundamentals remain concerning: the company reported $0.00 revenue in the latest quarter and a net loss of $-80,987,000.00 for the full year, despite revenue growth of 100.0% year-over-year, indicating early-stage biotech with no current commercial revenue. The scale of this purchase relative to prior trading activity and his expanded concentration warrant scrutiny into whether this reflects informed conviction or response to depressed valuation in a loss-making firm.

CEO Moulder Leon O Jr bought 60,000 shares (60.0K shares) for $1.1M at ZBIO; stock down 59.4% from 52-week high, company unprofitable.

Leon Moulder, Chief Executive Officer of Zenas BioPharma, executed 2 separate purchases totaling 60,000 (60.0K shares) for $1,067,200.00 ($1.1M) on consecutive days at an blended average price of $17.79, increasing his holdings by 3.5% to 1,786,039 shares (1.79M shares). The company is unprofitable with a net income of $-51,499,000.00 ($-51.5M) over its most recent full fiscal year and zero quarterly revenue, while the stock trades at $17.55, down -59.4% from its 52-week high of $43.17 and down -16.0% over the past 90 days. The CEO's prior ZBIO purchases show mixed outcomes: his January 2026 buys achieved +28.6% and +28.0% returns at the 90-day mark, but more recent transactions in late February and March have declined or remain immeasurable, and his cross-ticker buy track record shows a 30.77% 90d win rate with an average 90d return of -17.4%.

CEO bought 54,000 shares for $1,021,140 over 2 days at $18.91 avg; stock down 54.7% from high, 25.8% in 30d. Cluster buy pattern detected.

Leon Moulder, CEO, executed 2 separate purchases totaling 54,000 shares for $1,021,140 on 2026-03-30 and 2026-03-31 at a blended average price of $18.91, increasing his holdings by 3.2% to 1,726,039 shares. The timing follows a sharp 30-day decline of 25.8% and a 90-day decline of 46.2%, and the stock is currently -54.7% from its 52-week high of $43.17. At this same ticker over the past months, Moulder's prior 5 buy trades showed 30-day returns ranging from +31.7% to +55.7%, but his sole measurable 90-day outcome (from October 2025) returned -20.3%, indicating mixed execution. Fundamentally, the company carries a $-51,499,000 net loss in its most recent period with $0.00 revenue in the latest quarter, though annual revenue growth is reported at +100.0%. A cluster buy pattern is present with 2 other insiders purchasing within the past 14 days, suggesting coordinated or parallel confidence at depressed price levels.

CEO Leon Moulder buys 57,000 ZBIO shares at $17.96; stock now -54.3% from 52-week high, revenue collapsed -90.0%.

Leon Moulder Jr, the Chief Executive Officer, purchased 57,000 shares at $17.96 on 2026-02-02, increasing his stake to 423,155 shares (+15.6% vs prior holdings). This is his third consecutive purchase in 9 days (Jan 7, 8, 9, and now Feb 2), accumulating shares as ZBIO trades at $19.72, down -54.3% from its 52-week high of $43.17 and down -42.8% over the past 30 days. Fundamental performance is severely deteriorated: annual revenue declined -90.0% in the most recent fiscal year, the company generated $0.00 in latest quarterly revenue, and net income was -$51,499,000.00. His prior trades at ZBIO show mixed results—a 2025-02-18 purchase returned +65.1% at the 90-day mark, but the 2025-10-07 purchase returned -20.3%—meaning timing accuracy at this ticker is 50%. The purchase price of $17.96 sits below the current price of $19.72 but the margin is minimal, and the broader -42.8% 30-day decline and revenue collapse are material headwinds that merit scrutiny of whether conditions have stabilized or if further deterioration may follow.

CEO Moulder buys 100,000 shares ($1.6M) at ZBIO as stock falls 62.8% from 52-week high; 1 of 5 prior same-ticker buys showed positive 90d return.

Leon O Moulder Jr, Chief Executive Officer, executed 3 separate purchases totaling 100,000 shares for $1,639,000.00 at blended average price $16.39 across January 7–9, 2026, raising his holdings from 266.2K to 366.2K shares (+37.6%). The timing coincides with severe price weakness: the stock trades at $16.08, down 62.8% from its 52-week high of $43.17 and down 58.9% over the prior 30 days. Fundamentally, the company reported zero revenue in the latest quarter, a net loss of $-51,499,000.00, and annual revenue contracted 90.0% year-over-year. His same-ticker buying history at ZBIO shows mixed results: of his 5 prior buys, only 1 achieved a positive 90-day return, suggesting his timing calls at this ticker have not consistently preceded near-term recoveries. The magnitude of this purchase and its execution during acute drawdown warrant investor attention to whether the CEO perceives durable value or whether the acquisition reflects forced accumulation amid operational stress.

Insider MOULDER LEON O JR purchased 36,928 shares of ZBIO at $20.85; stock now at $27.76, +27.1% in 30 days; cluster of 5 other insider buys in past 14 days.

MOULDER LEON O JR purchased 36,928 shares at $20.85, establishing an initial position in ZBIO. The stock has subsequently risen to $27.76, reflecting a 30-day gain of +27.1% and a 90-day gain of +148.3% from the broader trading range. However, this insider's prior trading history at ZBIO shows mixed results: of 5 previous buys at this ticker, only 1 achieved a positive 90-day return (+65.1% on a 2025-02-18 purchase), while 4 buys resulted in 90-day losses ranging from -30.6% to -53.5%. Across all tickers, this insider's cross-ticker track record shows a 90-day win rate of only 11.11% with an average 90-day return of -33.2%, suggesting limited predictive accuracy. The company remains unprofitable with $-52.2M annual net income, zero latest-quarter revenue, and -90.0% annual revenue growth, indicating significant operational and financial challenges. The concurrent cluster of 5 other insider buys within the past 14 days is the only noteworthy coordinated activity, though without visibility into those insiders' identities or roles, the significance of this alignment cannot be determined.

CEO Leon Moulder Jr buys 25,000 ZBIO shares at $6.67; stock now at $6.43, down 75.0% from 52-week high.

Moulder bought 25,000 shares at $6.67 on 2025-02-18, increasing his holdings to 266.2K shares. The stock has declined significantly since the purchase, trading at $6.43 (-18.1% over 30 days, -38.4% over 90 days) and sitting 75.0% below its 52-week high of $25.68. His prior trades at ZBIO show a concerning pattern: 0 of 3 measurable prior buys were well-timed at the 90-day mark, with outcomes ranging from -1.5% to -53.5% over 90 days. His cross-ticker track record reveals a 0.00% win rate on 8 prior buys with an average 90-day return of -49.2%. The company is posting operating losses ($-38.6M net income on $50.0M revenue) despite a $268.7M market cap, adding fundamental risk to the accumulation pattern.

CEO Leon O Moulder Jr buys 70,000 shares across 2 transactions (totaling $718,100.00) at ZBIO as stock down -50.7% in 30 days

Leon O Moulder Jr, Chief Executive Officer, executed 2 separate purchases totaling 70,000 shares for $718,100.00 on December 3–4, 2024, at blended average price $10.26, increasing his post-transaction holdings to 241.2K shares (+40.9% vs pre-transaction). This buy activity occurs after a sharp 30-day decline of -50.7%, with the stock trading -61.7% below its 52-week high of $25.68. His prior 5 trades at ZBIO (September through November 2024) were all buys; the measurable 30-day returns on three of those ranged from +12.5% to +19.4%. The timing of this CEO purchase near a recent low, combined with the company's revenue of $50.0M against net losses of $-38.6M, warrants investor attention to the company's current operational trajectory and whether this activity reflects management's assessment of near-term prospects.

ZBIO CEO Moulder buys 10,000 shares ($148.9K) at $14.89 avg; stock down 51.5% from 52-wk high, currently $12.45.

Leon O Moulder Jr, the Chief Executive Officer, executed 2 separate purchases totaling 10,000 shares for $148,925.00 (blended average $14.89) on November 18–19, 2024. The stock has declined 46.4% over the past 30 days and trades 51.5% below its 52-week high of $25.68, now at $12.45. Moulder's 4 prior ZBIO purchases (September 18–20, 2024) each posted 30-day returns between +12.5% and +19.4%, suggesting his previous ZBIO timing proved constructive at that short horizon; however, none of those trades has yet reached the 90-day mark to confirm longer-term outcome. The company is unprofitable (net income $-38,606,000.00 against revenue of $50,000,000.00), which contextualizes the current valuation pressure and the CEO's willingness to add shares during a sharp drawdown.

CEO Moulder Leon O Jr acquired 20,000 shares for $360,819.97 across 4 purchases; cluster buy pattern with 6 other insiders in past 14 days at ZBIO (IPO+6 trading days).

Leon O Moulder Jr, Chief Executive Officer of Zenas BioPharma, purchased 20,000 shares totaling $360,819.97 through 4 separate transactions between September 18–20, 2024, at prices ranging from $17.88 to $18.97 (blended average $18.04). The current price stands at $19.00. Notably, this acquisition occurs in a cluster context: 6 other insiders also bought within the past 14 days, establishing a synchronized buying pattern across the leadership team. This multi-insider activity during the company's first full week as a public company (ZBIO listed 6 trading days prior) warrants investor attention as it reflects early insider positioning at the post-IPO stage. Post-transaction holdings are 1,672,039 shares, an increase of 20,000 shares or 1.2% over the prior position.